Benefits
Appetite as a traditional bitter stomachic
A German medical encyclopedia lists a Commission E monograph for condurango bark in loss of appetite, and an EU veterinary assessment notes that in human medicine it is used as a bitter stomachic at an average 2 to 4 g a day. No human trial has measured appetite with condurango, so this use rests on tradition alone.
Digestive comfort in German herbal practice
A German phytotherapy reference lists condurango for loss of appetite and indigestion (dyspeptic complaints) and notes its use in combination tonics and tablets. The EMA's herbal committee and ESCOP have not reviewed it, and no study has measured digestive comfort with the bark alone or in these blends.
Saliva and stomach juice flow as a bitter stimulus
An EU veterinary assessment states that the bitter taste of condurango stimulates appetite and favors saliva and gastric juice secretion, the usual rationale for taking bitters before meals. No human or animal measurement of secretion with condurango was found; small human studies exist only for other bitters such as gentian.
Mechanism of action
Pregnane glycosides (condurangin)
The bitter principle, condurangin, is a mixture of pregnane glycosides built on steroid-like cores carrying several deoxy sugars, typical of the milkweed family. Chemists have isolated condurangoglycosides A and C and many related compounds from the bark. The EU assessment notes these glycosides dissolve more easily in cold than in warm water.
Cell toxicity linked to reactive oxygen species in lab tests
In cultured cancer cells, condurango extracts raised reactive oxygen species, damaged DNA and triggered programmed cell death; the antioxidant N-acetyl cysteine blocked much of this. This describes how the extract harms cells in a dish, at concentrations no one has linked to oral doses, and is not a benefit shown in people.
Bitterness value as a quality measure
Bitter herbs are graded by a bitterness value. A German reference gives condurango a value of 600 to 800, and a draft Austrian pharmacopoeia monograph sets a minimum of 1000, well below the 3000 minimum the European Pharmacopoeia sets for bogbean leaf, so condurango is a milder bitter than bogbean.
Clinical trials
Lab study: an ethanol extract of condurango (Boiron) at 15 to 180 micrograms per mL tested on HeLa cervical cancer and PC3 prostate cancer cells, with WRL-68 liver cells (called transformed in the abstract, normal in the methods) and mouse blood immune cells as non-cancer controls; partly funded by Boiron, which also supplied the extract; using flow cytometry, immunoblotting and RT-PCR (Bishayee et al. 2015, J Pharmacopuncture)
Human cancer cell lines, a human liver cell line and mouse blood cells in culture; no people took condurango.
The extract killed HeLa cells more than PC3 cells and showed minimal toxicity to the liver cell line and mouse blood cells. Cell death depended on reactive oxygen species, since N-acetyl cysteine blocked it, and involved Fas receptor, TNF-alpha and mitochondrial changes. Cell work only; it does not show any effect in people.
Independent lab study: 2% Gonolobus condurango mother tincture and homeopathic dilutions (C6, C30, D6) compared with known histone deacetylase (HDAC) inhibitors and an ethanol control mainly in the HCC38 triple-negative breast cancer cell line, with HeLa cells in supplementary tests; authors declared no competing interests (Vajen et al. 2025, BMC Complement Med Ther)
Human breast cancer cell lines in culture (condurango tested in HCC38, with HeLa cells in supplementary tests); no people took condurango.
Unlike the reference HDAC inhibitors, condurango did not raise histone acetylation, which contradicts an earlier report that it acts as an HDAC inhibitor, and it did not switch on the two tumor-suppressing microRNAs tested. The mother tincture raised apoptosis about 2.5-fold in HCC38 cells, as the reference inhibitor did, but not in HeLa cells; the homeopathic dilutions had no effect. Cell work only.
Animal study: rats fed benzo[a]pyrene (50 mg/kg) developed lung tumors over 4 months and then received 0.06 mL of a diluted ethanolic condurango extract (1 mL extract in 20 mL water) by mouth twice daily for 1, 2 or 3 months, compared with alcohol-vehicle and untreated cancer groups; partly funded by Boiron; a 2015 erratum corrected the abstract's methods (Sikdar et al. 2014, J Pharmacopuncture)
Sprague-Dawley rats (the methods describe groups of 5, while the tables report 6 per group); no people.
Lung tissue in treated rats showed gradual repair on microscopy by 3 months, although the figure caption labels these sections Condurango 30C, the homeopathic preparation the same group tested in a separate rat study. Reactive oxygen species rose and antioxidant enzymes fell in treated lungs, and markers of programmed cell death increased. One research group, a rat model with a chemical carcinogen, and no human data; it is not evidence of an anticancer effect in people.
Lab study: ethanolic extracts of aloe (Barbadensis miller) and condurango tested alone and as a 1:1 combination at 10 to 1,000 micrograms per mL on HeLa cervical cancer and HepG2 liver cancer cells (Maqbool et al. 2021, Asian Pac J Cancer Prev)
Human cancer cell lines in culture; no normal cells tested and no people took the extracts.
Condurango alone needed about 459 (HeLa) and 477 (HepG2) micrograms per mL to halve cell viability; the combination with aloe needed about 50 micrograms per mL. The combination raised p53 and lowered the antioxidants glutathione, SOD and catalase. High concentrations in a dish, a two-herb combination, and no human relevance shown.